Global Dental Leaders to Convene in Shanghai for FDI World Dental Congress 2025
SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the oral health profession, will take place in Shanghai, China, from September 9–12, 2025, co-hosted by Chinese Stomatological Association and Reed Sinopharm Exhibitions. Organized annually in different countries, the WDC highlights the importance of oral health in securing overall health...
Singapore-Based Innovative Biomedical Start-Up Achieves ‘Strategic Triumph’ to Conquer Chinese Med-Tech Market
NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China is the largest and most important success in the company's history; product approval in China was the company's most important strategic and operational goal Syntellix had previously already been granted the accelerated...
Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure
ZUG, Switzerland, July 23, 2025 /PRNewswire/ -- Berlin Heals and the C-MIC II Investigators today announced the publication of the C-MIC II trial results in the European Journal of Heart Failure. The study, titled "Cardio-microcurrent Device Treatment for Heart Failure with Reduced Ejection Fraction: Results from the C-MIC II Open Label Randomized Controlled Trial," was previously presented...
Zylox-Tonbridge Issues Positive Profit Alert, Expects Over RMB 115 Million in 1H 2025 Net Profit
HANGZHOU, China, July 23, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, "Zylox-Tonbridge" or the "Company"), a leading medical device company in China's peripheral and neurovascular interventional market, today announced a positive profit alert for the six months ended June 30, 2025. Based on preliminary unaudited figures, the Company expects to record revenue of over RMB 480 million,...
Samsung Biologics reports second quarter 2025 financial results
Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion Recorded Q2'25 consolidated operating profit of KRW 475.6 billion Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial...
LG AI Research Showcases ‘EXAONE Ecosystem’ at LG AI Talk Concert 2025
Pioneering AI Transformation from Bio to Business Intelligence SEOUL, South Korea, July 22, 2025 /PRNewswire/ -- LG AI Research hosted its "LG AI Talk Concert 2025" today at the LG Sciencepark Convergence Hall in Magok, Seoul, showcasing the evolution of its EXAONE ecosystem. The event highlighted the culmination of five years of AI development, featuring advanced AI models and...
BostonGene Receives Frost & Sullivan’s 2025 North American Enabling Technology Leadership Award for Redefining Precision Oncology with AI and Multiomics Innovation
BostonGene's comprehensive AI-powered platform integrates multiomics data to accelerate discovery, reduce development risk and advance precision oncology across all stages the R&D continuum SAN ANTONIO, July 22, 2025 /PRNewswire/ -- Frost & Sullivan has named BostonGene the recipient of the 2025 North American Enabling Technology Leadership Award in recognition of the company's pioneering role in advancing precision oncology. BostonGene's clinically validated,...
Kolmar Korea Launches Full Operation of 2nd US Factory, Establishing K-Beauty’s ‘Tariff Safe Zone’ in America
New 17,805㎡ facility completed in Pennsylvania with an annual production capacity of 300 million units Full ODM production capabilities in the US — from color cosmetics to skincare and suncare — mitigating tariff and supply chain risks 'MADE BY KOLMAR' world-class manufacturing technology localized to the US market OLYPHANT, Pa. and...
A novel oral treatment for Alzheimer’s: Actinogen’s pivotal trial currently recruiting participants in the US
All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months SYDNEY, July 22, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is encouraging individuals and...
Telix Reports $204M Revenue, Up 63% YOY
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. Q2 2025 Highlights Q2 2025 unaudited group revenue of...
